Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biolase Q4 EPS $(1.76) Beats $(2.55) Estimate, Sales $13.49M Miss $13.55M Estimate

Author: Benzinga Newsdesk | March 21, 2024 04:16pm
Biolase (NASDAQ:BIOL) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.55) by 30.98 percent. This is a 98.63 percent increase over losses of $(128.00) per share from the same period last year. The company reported quarterly sales of $13.49 million which missed the analyst consensus estimate of $13.55 million by 0.44 percent. This is a 3.99 percent decrease over sales of $14.05 million the same period last year.

Posted In: BIOL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist